- NASDAQ:NVAX adds a futrther 0.93% to Wednesday's gains as broader markets bounce back.
- NVAX is one biotech firm to watch after partnering with Serum Institute of India.
- Novavax investors await results of Phase 3 of its clinical trials.
It has been a historic year for biotech firms as the emergency need for a COVID-19 vaccine has put many small firms on the radars of investors. NASDAQ:NVAX is at the top of that list and after gaining over 4600% year to date, the stock still could have room to move if the results of its Phase 3 clinical trials are successful. On Thursday, Novavax rose 0.93% to close the day at $111.02, which means the stock is still trading at a 40% discount from its 52-week high of $189.40. The stock is trading right at its 50-day moving average which shows how flat shares have been even through some encouraging announcements from the firm.
In late September, the Maryland-based biotech company announced a partnership with the largest manufacturer of vaccines in the world at the Serum Institute of India. The deal led to estimates of over 2 billion annual doses of its vaccine candidate: NVX‑CoV2373 for low-income countries which includes India. Considering these reports from the company, the stock has not moved up over the past couple of months which may be an indication that investors are exercising caution over which biotech company will emerge as the successful candidate.
NVAX stock news
As the global economy continues its volatility heading into the final quarter of 2020, investors who are looking to Novavax as a possible horse to back in the race for a vaccine may want to take the plunge now before it is too late. Expect the stock to get a boost if a successful Phase 3 result is reported, and with a mean analyst price target of $227.60, these may be the lowest levels the stock sees for quite some time.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD clings to daily gains above 1.0650
EUR/USD gained traction and turned positive on the day above 1.0650. The improvement seen in risk mood following the earlier flight to safety weighs on the US Dollar ahead of the weekend and helps the pair push higher.
GBP/USD recovers toward 1.2450 after UK Retail Sales data
GBP/USD reversed its direction and advanced to the 1.2450 area after touching a fresh multi-month low below 1.2400 in the Asian session. The positive shift seen in risk mood on easing fears over a deepening Iran-Israel conflict supports the pair.
Gold holds steady at around $2,380 following earlier spike
Gold stabilized near $2,380 after spiking above $2,400 with the immediate reaction to reports of Israel striking Iran. Meanwhile, the pullback seen in the US Treasury bond yields helps XAU/USD hold its ground.
Bitcoin Weekly Forecast: BTC post-halving rally could be partially priced in Premium
Bitcoin price shows no signs of directional bias while it holds above $60,000. The fourth BTC halving is partially priced in, according to Deutsche Bank’s research.
Week ahead – US GDP and BoJ decision on top of next week’s agenda
US GDP, core PCE and PMIs the next tests for the Dollar. Investors await BoJ for guidance about next rate hike. EU and UK PMIs, as well as Australian CPIs also on tap.